🇺🇸 FDA
DSHEA dietary supplement · NDI varies by source · no FDA authorized health claim
Fucoxanthin (Brown-algae xanthophyll)
Also known as: Allenic xanthophyll · Fucoxanthinol (active metabolite) · Brown seaweed carotenoid
Mechanism of action
- UCP1 upregulation (white-to-brown adipocyte conversion signal)
- AMPK activation
- NRF2 antioxidant response
- NF-κB inhibition
- Anti-obesity adipokine modulation
Molecular + tissue targets
- Visceral adipose tissue UCP1
- AMPK pathway
- Hepatic lipid metabolism
- Glucose homeostasis markers
Dosage range
2.4-12 mg/day (often as combination formulation · Xanthigen-style trials use 2.4 mg/day for 16 weeks)
Safety notes
Generally well tolerated in published RCTs at 2.4-12 mg/day for 12-16 weeks · pregnancy/lactation data limited · iodine content varies by source seaweed (consider thyroid-sensitive individuals)
Cross-market regulatory status
🇪🇺 EFSA
No EU authorized health claim under Reg 432/2012 · novel food evaluation case-by-case for specific extraction processes
🇧🇷 ANVISA
RDC 243/2018 dietary supplement framework · IN 28/2018 alegação funcional not authorized for fucoxanthin specifically
Common use cases
- metabolic syndrome adjunct (research context)
- body weight markers
- hepatic lipid markers
- glucose tolerance signal
Cross-reference
Health goals: weight management longevity stack heart health glp 1 companion
Lifestyles: keto intermittent fasting senior 60 plus
Full dossier: /ingredients/fucoxanthin/
Machine-readable JSON: /api/nc/fucoxanthin.json